首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

2007997

腦腫瘤市場：依適應症、治療類型、通路和地區分類

Brain Cancer Market, By Indication, By Treatment Type, By Distribution Channel, By Geography

出版日期: 2026年03月02日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026年腦腫瘤市值為47.614億美元，預計到2033年將達到65.866億美元。預計從2026年到2033年，其複合年成長率將達到8.3%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	47.614億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	8.30%	2033年市場規模預測：	65.866億美元

全球腦瘤市場是腫瘤學領域最重要、最具挑戰性的細分市場之一，涵蓋多種起源於腦組織或從其他器官轉移至腦部的惡性腫瘤。腦腫瘤，包括原發性腫瘤（如多形性膠質母細胞瘤、星狀細胞瘤和少突膠質細胞瘤）以及轉移性腦瘤，每年影響全球數十萬名患者，由於血腦障壁和神經組織的脆弱性，其治療面臨著極其複雜的挑戰。

該市場涵蓋多種治療方法，包括放射線治療、化療、標靶治療和新型免疫療法。製藥公司、醫療設備製造商和生技公司都在研發方面投入大量資金，以滿足尚未滿足的醫療需求。全球腦腫瘤發生率的不斷上升，加上人口老化、先進神經影像技術帶來的診斷能力提升以及人們對早期檢測意識的日益增強，使得該市場成為醫療創新的焦點，推動了對新型治療方法和精準醫療策略的大量投資，旨在改善患者的治療效果和生活品質。

市場動態

全球腦腫瘤市場受多種強勁的市場促進因素推動，這些因素持續擴大市場機會並促進治療方法的進步。主要市場促進因素包括全球腦腫瘤發生率的上升，這歸因於人口老化、環境暴露、遺傳易感性以及診斷能力的提高，使得早期發現以往未確診的病例成為可能。神經影像學、外科手術技術和放射治療設備的創新，以及標靶治療治療和免疫療法的研發，顯著提高了治療的準確性和有效性，透過改善患者預後和拓展治療選擇，推動了市場成長。

此外，製藥公司在研發方面的巨額投資、不斷上漲的醫療成本、日益擴大的公眾意識宣傳活動以及支持孤兒藥研發的法規結構，都在加速新療法的上市。然而，該市場也面臨諸多限制因素，包括腦腫瘤的複雜性（由於血腦障壁的保護機制，腦腫瘤通常對傳統療法產生抗藥性）、神經系統藥物研發成本極高、監管核准過程嚴格、某些高度侵襲性腫瘤（例如多形性膠質母細胞瘤）的治療選擇有限，以及現有治療方法帶來的嚴重副作用會影響患者的生活品質。

此外，某些腦腫瘤亞型患者數量相對較少，給製藥公司帶來了商業性挑戰；同時，醫療資源分配不均和治療費用高昂限制了其在發展中地區的市場滲透。儘管面臨這些挑戰，但精準醫療技術的進步、能夠有效穿過血腦障壁的新型藥物遞送系統的開發、免疫療法的廣泛應用、人工智慧在診斷和治療方案製定中的應用、聯合治療療法的日益普及，以及學術機構、生物技術公司和大型製藥公司之間合作的加強，都為腦腫瘤治療領域的創新和新收入來源的創造提供了巨大的市場機遇。

本次調查的主要特點。

本報告對全球腦腫瘤市場進行了詳細分析，顯示了以 2025 年為基準年，預測期（2026-2033 年）的市場規模和複合年成長率（%）。
此外，它還指出了每個細分市場的潛在商機，並說明了該市場中一個有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業所採取的競爭策略的關鍵見解。
本報告根據以下參數對全球腦腫瘤市場的主要企業參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
透過利用本報告中提出的見解，企業行銷負責人和經營團隊可以就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
本報告面向該產業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過分析全球腦腫瘤市場時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第8章競爭情勢

Novocure
Servier
Day One Biopharmaceuticals
Jazz Pharmaceuticals
Chimerix
Novartis
Roche
Bayer
AstraZeneca
Merck &Co.
Kazia Therapeutics
CNS Pharmaceuticals
Carthera
Plus Therapeutics
Genenta Science

第9章分析師建議

機會
分析師意見
Coherent Opportunity Map

第10章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI9360

Brain Cancer Market is estimated to be valued at USD 4,761.4 Mn in 2026 and is expected to reach USD 6,586.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.3% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 4,761.4 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.30%	2033 Value Projection:	USD 6,586.6 Mn

Global brain cancer market represents one of the most critical and challenging segments within the oncology therapeutics landscape, encompassing a diverse array of malignant tumors that originate in brain tissue or spread to the brain from other organs. Brain cancers, including primary tumors such as glioblastoma multiforme, astrocytomas, oligodendrogliomas, and metastatic brain tumors, affect hundreds of thousands of patients worldwide annually, presenting significant therapeutic complexities due to the blood-brain barrier and the delicate nature of neurological tissue.

The market encompasses various treatment modalities including surgical interventions, radiation therapy, chemotherapy, targeted therapies, and emerging immunotherapeutic approaches, with pharmaceutical companies, medical device manufacturers, and biotechnology firms investing substantially in research and development to address the substantial unmet medical needs. The increasing incidence of brain cancers globally, coupled with aging populations, improved diagnostic capabilities through advanced neuroimaging technologies, and growing awareness about early detection, has positioned this market as a focal point for healthcare innovation, driving significant investments in novel therapeutic approaches and precision medicine strategies that aim to improve patient outcomes and quality of life.

Market Dynamics

The global brain cancer market is propelled by several compelling drivers that continue to expand market opportunities and therapeutic advancement. The primary market drivers include the rising global incidence of brain tumors attributed to factors such as aging demographics, environmental exposures, genetic predispositions, and improved diagnostic capabilities that enable earlier detection of previously undiagnosed cases. Technological innovations in neuroimaging, surgical techniques, radiation therapy equipment, and the development of targeted therapies and immunotherapies have significantly enhanced treatment precision and efficacy, driving market growth through improved patient outcomes and expanded treatment options.

Additionally, substantial investments in research and development by pharmaceutical companies, increased healthcare expenditure, growing awareness campaigns, and supportive regulatory frameworks for orphan drug development have accelerated the introduction of novel therapeutics into the market. However, the market faces significant restraints including the complex nature of brain cancers that often resist conventional treatments due to the blood-brain barrier's protective mechanism, extremely high research and development costs associated with neuropharmaceutical development, stringent regulatory approval processes, limited treatment options for certain aggressive tumor types like glioblastoma multiforme, and the substantial side effects associated with current treatment modalities that impact patient quality of life.

Furthermore, the relatively small patient populations for specific brain cancer subtypes present commercial challenges for pharmaceutical companies, while healthcare access disparities and high treatment costs limit market penetration in developing regions. Despite these challenges, the market presents substantial opportunities through the advancement of precision medicine approaches, development of novel drug delivery systems that can effectively cross the blood-brain barrier, expansion of immunotherapy applications, integration of artificial intelligence in diagnosis and treatment planning, growing emphasis on combination therapies, and increasing collaborative efforts between academic institutions, biotechnology companies, and pharmaceutical giants that are fostering innovation in brain cancer therapeutics and creating new revenue streams.

Key Features of the Study

This report provides in-depth analysis of the global brain cancer market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global brain cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novocure, Servier, Day One Biopharmaceuticals, Jazz Pharmaceuticals, Chimerix, Novartis, Roche, Bayer, AstraZeneca, Merck & Co., Kazia Therapeutics, CNS Pharmaceuticals, Carthera, Plus Therapeutics, and Genenta Science
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global brain cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global brain cancer market

Market Segmentation

Indication Insights (Revenue, USD Mn, 2021 - 2033)
- Meningioma
- Glioblastoma
- Pituitary Tumors
- Others (Oligodendroglioma, Astrocytoma, etc.)
Treatment Type Insights (Revenue, USD Mn, 2021 - 2033)
- Chemotherapy
- Carmustine
- Temozolomide
- Combination Drugs (Lomustine, Procarbazine, and Vincristine)
- Targeted Therapy
- Bevacizumab
- Larotrectinib
- Entrectinib
- Others (Dinutuximab, Naxitamab-gqgk etc.)
- Immunotherapy
- Dostarlimab
- Granulocyte-macrophage colony-stimulating factor
- Pembrolizumab
Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novocure
- Servier
- Day One Biopharmaceuticals
- Jazz Pharmaceuticals
- Chimerix
- Novartis
- Roche
- Bayer
- AstraZeneca
- Merck & Co.
- Kazia Therapeutics
- CNS Pharmaceuticals
- Carthera
- Plus Therapeutics
- Genenta Science

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Brain Cancer Market, By Indication
- Global Brain Cancer Market, By Treatment Type
- Global Brain Cancer Market, By Distribution Channel
- Global Brain Cancer Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trends

4. Global Brain Cancer Market, By Indication, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment
Meningioma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Glioblastoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Pituitary Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others (Oligodendroglioma, Astrocytoma, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Brain Cancer Market, By Treatment Type, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  - Carmustine
  - Temozolomide
  - Combination Drugs (Lomustine, Procarbazine, and Vincristine)
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  - Bevacizumab
  - Larotrectinib
  - Entrectinib
  - Others (Dinutuximab, Naxitamab-gqgk, etc.)
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  - Dostarlimab
  - Granulocyte-macrophage colony-stimulating factor
  - Pembrolizumab

6. Global Brain Cancer Market, By Distribution Channel, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Brain Cancer Market, By Region, 2021 - 2033, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Novocure
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Servier
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Day One Biopharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Jazz Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Chimerix
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Kazia Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
CNS Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Carthera
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Plus Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Genenta Science
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies